What Hormones to Test and When - FSH LH Estradiol AMH and More

Hormone Testing for Women: Timing Is Everything

Hormone testing in women is fundamentally different from hormone testing in men, and the reason comes down to one thing: the menstrual cycle. Men produce hormones in a relatively steady state, with mild daily fluctuations but no dramatic cyclical changes. Women, on the other hand, have hormones that shift dramatically over the course of a roughly 28-day cycle. Testing on the wrong day of the cycle can give you a result that looks abnormal when it is actually perfectly normal, or normal when it is actually a problem. Knowing when to test which hormone is the foundation of meaningful results.

This video walks through the major hormones that women should know about, when in the cycle they should be tested, and what the results actually mean. It is particularly relevant for women dealing with irregular cycles, fertility concerns, or unexplained symptoms that might have a hormonal basis. Even for women who are not actively trying to conceive, understanding your hormone panel is valuable for overall health optimization.

The Key Hormones and Their Optimal Testing Windows

FSH (follicle-stimulating hormone) and LH (luteinizing hormone) are pituitary hormones that regulate ovarian function. FSH stimulates the growth of ovarian follicles (which contain eggs), while LH triggers ovulation when it surges mid-cycle. Testing both on day 2-4 of the menstrual cycle (counting day 1 as the first day of full flow) gives you a baseline reading of how hard your pituitary is working to stimulate your ovaries.

An elevated FSH on day 2-4 suggests diminished ovarian reserve, meaning the ovaries are not responding as robustly to stimulation and the pituitary is compensating by producing more FSH. This is a normal part of aging, with FSH gradually rising through a woman's thirties and forties, but a high FSH in a younger woman can signal premature ovarian aging. The ratio of LH to FSH is also informative. An LH-to-FSH ratio greater than 2:1 is commonly seen in PCOS, though it is not diagnostic on its own.

Estradiol, Progesterone, and Their Cycle-Specific Windows

Estradiol (E2), the primary active estrogen, should also be tested on day 2-4 for baseline assessment. At this point in the cycle, estradiol should be relatively low (typically 20-80 pg/mL). An elevated baseline estradiol can suppress FSH, making FSH look artificially normal even when ovarian reserve is actually declining. This is why testing both together on the same day gives you a more complete picture than either one alone.

Progesterone testing follows a completely different timeline. Progesterone is produced by the corpus luteum (the structure that forms after an egg is released) and peaks in the mid-luteal phase, approximately 7 days after ovulation. For a woman with a regular 28-day cycle, this means testing on approximately day 21. For women with longer or shorter cycles, the timing should be adjusted to 7 days before the expected next period. A progesterone level above 3 ng/mL generally confirms ovulation, while levels above 10 ng/mL suggest robust ovulatory function.

Testing progesterone on the wrong day is one of the most common mistakes in hormone evaluation. A progesterone drawn on day 14, before the corpus luteum has had time to produce significant amounts, will look low even in a woman who ovulates perfectly. This can lead to an incorrect diagnosis of anovulation or luteal phase deficiency when the issue was simply testing at the wrong time.

AMH: The Ovarian Reserve Marker That Changed Fertility Medicine

Anti-Mullerian hormone (AMH) is produced by the small antral follicles in the ovaries and reflects the size of the remaining follicle pool. Unlike FSH and estradiol, AMH is relatively stable throughout the menstrual cycle, which makes it one of the more convenient hormones to test because timing is less critical. It can be drawn on any day of the cycle and still provide meaningful information.

AMH has become a cornerstone of fertility assessment because it gives a direct estimate of ovarian reserve. Higher AMH levels indicate a larger follicle pool (more eggs remaining), while lower levels suggest diminished reserve. Normal values depend on age, but generally, an AMH above 1.0 ng/mL is considered adequate, while levels below 0.5 ng/mL suggest significantly reduced reserve.

It is important to understand what AMH does and does not tell you. AMH reflects quantity, not quality. A woman with a low AMH may still have eggs of excellent quality, while a woman with a high AMH may have quality issues related to age or other factors. AMH also does not predict the ability to conceive naturally in the short term. It is most useful for predicting response to fertility treatments and estimating the timeline of reproductive aging.

Thyroid Hormones and Their Reproductive Connection

Thyroid function testing belongs in any thorough female hormone panel because thyroid disorders are common in women and have direct effects on menstrual regularity, fertility, and pregnancy outcomes. TSH (thyroid-stimulating hormone) is the primary screening test, with T4 and T3 (both free forms) providing additional detail when TSH is abnormal or when symptoms suggest thyroid dysfunction despite a normal TSH.

For women trying to conceive, the target TSH is tighter than for the general population. Most reproductive endocrinologists aim for TSH below 2.5 mIU/L, compared to the general reference range of 0.4-4.0 mIU/L. Subclinical hypothyroidism (TSH between 2.5 and 4.0 with normal free T4) may impair fertility and increase miscarriage risk, which is why the stricter target matters in a reproductive context.

Thyroid antibodies (TPO and thyroglobulin antibodies) should be checked at least once, as autoimmune thyroid disease (Hashimoto's) is common in women of reproductive age and can affect fertility and pregnancy even when TSH is normal. The presence of antibodies with a borderline TSH warrants more aggressive monitoring and potentially treatment.

Testosterone and DHEA-S in Women

Testosterone and DHEA-S testing in women is relevant for several scenarios. Elevated levels may indicate PCOS, adrenal dysfunction, or rarely, androgen-secreting tumors. Low levels may contribute to low libido, fatigue, and poor muscle maintenance, particularly in peri- and post-menopausal women.

Total testosterone, free testosterone, and DHEA-S should be drawn on day 2-4 of the cycle along with FSH, LH, and estradiol for a full hormonal snapshot. SHBG (sex hormone-binding globulin) is also worth including because it determines how much of the total testosterone is biologically active. A woman with a normal total testosterone but low SHBG may have elevated free testosterone and androgenic symptoms, while the reverse (high SHBG with normal total T) may produce symptoms of testosterone deficiency.

The relationship between insulin and SHBG is clinically relevant. Insulin suppresses SHBG production, so women with insulin resistance (common in PCOS) tend to have low SHBG, which amplifies the effect of whatever testosterone is present. Addressing insulin resistance through diet, exercise, and sometimes metformin can raise SHBG and reduce free testosterone without directly targeting the androgens.

Building Your Testing Protocol

For a full female hormone assessment, the ideal approach is a two-draw protocol. The first draw happens on cycle day 2-4 and includes FSH, LH, estradiol, total and free testosterone, DHEA-S, SHBG, AMH, TSH, free T4, free T3, thyroid antibodies, prolactin, fasting insulin, and fasting glucose. The second draw happens approximately 7 days after ovulation (day 21 in a 28-day cycle) and includes progesterone.

Women with irregular cycles face a timing challenge. If you do not know when day 3 is because your periods are unpredictable, your provider may test on any day and interpret the results with that caveat in mind. Alternatively, ovulation predictor kits can help identify the LH surge, and progesterone can be drawn 7 days after that surge is detected.

For post-menopausal women, cycle timing is irrelevant since there is no active menstrual cycle. A single thorough draw including FSH, estradiol, testosterone, DHEA-S, SHBG, thyroid panel, metabolic markers, and bone-related markers (vitamin D, calcium, PTH) provides the information needed for menopausal hormone management.

Beyond the Panel: Using Your Results for Ongoing Health Management

Getting the right tests at the right time is only the beginning. The real value comes from interpreting the results in context and using them to guide decisions over time. A single hormone panel provides a snapshot. Serial panels over months and years reveal trends that are far more informative than any individual result. A gradually rising FSH over three annual panels tells a clearer story about ovarian aging than any single FSH value, no matter how precisely timed.

For women in their thirties who are not actively trying to conceive but want to preserve future fertility options, periodic AMH and FSH testing (annually or every 18 months) provides early warning of accelerated ovarian aging. This information can influence decisions about egg freezing, family planning timelines, and lifestyle modifications aimed at preserving reproductive health. The window for these interventions closes gradually, and data-driven awareness ensures it does not close without your knowledge.

Perimenopause presents its own monitoring challenges. Hormones become increasingly erratic in the years before menopause, with cycles varying in length and ovulatory status from month to month. During this phase, single blood draws may be misleading because the hormonal fluctuations are so pronounced. Tracking symptoms alongside occasional labs, and understanding that variability is the hallmark of perimenopause rather than a sign of a specific problem, helps avoid overreaction to individual results.

The integration of home testing options (LH strips for ovulation detection, basal body temperature tracking, and emerging digital health platforms that combine multiple data streams) with periodic professional lab work creates a full monitoring approach that is both practical and informative. These tools allow women to gather daily data points that provide context for the periodic lab work, creating a richer dataset for clinical decision-making than either approach provides alone.